Skip to content
2000
Volume 11, Issue 1
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

A number of studies have identified differential kavalactone activity against a variety of molecular targets, including P glycoprotein (Pgp), platelet monoamine oxidase (MAO-B), transcription factor binding domains, pregnane X (PXR) and GABA receptors, and cytochrome P450 and cyclo-oxygenase (COX) enzymes. The molecular structure of the kavalactones possesses a pharmacophore for several of these targets. In most cases, conformational stability is more significant than the substituents present. The analysis of these pharmacophores provides important insights for future medicinal chemistry-based approaches to kavalactone-type drugs.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955711793564088
2011-01-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955711793564088
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test